Dr. Gary R. Macvicar, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Chicago, Pritzker School of Medicine (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,070
Licensed in Illinois since 2005, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: University of Chicago, Pritzker School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
IL license 036114093 (first issued 2005; active) -
Hematology (Internal Medicine) Physician
IL license 036 -
Medical Oncology Physician
IL license 036114093 (first issued 2005; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Saint Francis Medical Center Peoria, IL
- Osf Saint Elizabeth MDl Ctr Peru, IL
- Carle Health Methodist Hospital Peoria, IL
- Saint James Hospital Pontiac, IL
- Carle Health Pekin Hospital Pekin, IL
Medical groups
- Oncology-Hematology Associates of Central Illinois P C (67 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,070
- Services billed
- 225,991
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 35,190 | 56 |
| Injection, ferric carboxymaltose, 1 mg | 24,000 | 26 |
| Injection, azacitidine, 1 mg | 12,900 | 17 |
| Injection, pembrolizumab, 1 mg | 12,400 | 20 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 9,936 | 103 |
| Injection, nivolumab, 1 mg | 9,641 | 11 |
| Injection, oxaliplatin, 0.5 mg | 8,800 | 11 |
| Injection, denosumab, 1 mg | 7,140 | 37 |
| Injection, aprepitant, 1 mg | 6,890 | 25 |
| Injection, paclitaxel, 1 mg | 5,019 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Peoria, IL | 343 |
| Abiraterone Acetate | 324 |
| Dexamethasone Other prescribers in Peoria, IL | 134 |
| Anastrozole Other prescribers in Peoria, IL | 129 |
| Acyclovir Other prescribers in Peoria, IL | 113 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Peoria, IL | 90 |
| Prochlorperazine Maleate Other prescribers in Peoria, IL | 68 |
| Eliquis (apixaban) Other prescribers in Peoria, IL | 67 |
| Ondansetron Hcl Other prescribers in Peoria, IL | 66 |
| Levothyroxine Sodium Other prescribers in Peoria, IL | 62 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 6 companies. The companies reported $1,014,238 in research payments for these studies, mostly to the institutions running them.
- An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1,L1 …
Merck Sharp & Dohme LLC - Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-lin…
E.r. Squibb & Sons, L.l.c. - A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation MK-7684A Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic…
Merck Sharp & Dohme LLC - A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK 3475A Versus Intravenous Pembrolizumab, in the First-line Tr…
Merck Sharp & Dohme LLC - A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC That Progressed On or After Prior Tr…
Merck Sharp & Dohme LLC - Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Daiichi Sankyo Inc. · Recruiting · NCT07129993 - Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC
Genentech, Inc. - Phase III Ipatasertib plus abiraterone in mCRPC 1st Line
Genentech, Inc. - Atezolizumab Carboplatin Etoposide Tiragolumab or Placebo in 1L ES SCLC
Genentech, Inc. - Study name not reported
Organon Llc
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.